Modafinil Viatris

Modafinil, the active ingredient in Modafinil Viatris, is a eugeroic presented as a unknown/unknown for oral use. It treats excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorder in adults.

GNH USA supplies Modafinil Viatris as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Modafinil is a eugeroic that promotes wakefulness in disorders characterized by excessive daytime sleepiness.

- Narcolepsy: reduces daytime sleep attacks and improves alertness. - Obstructive sleep apnea (excessive daytime sleepiness): mitigates residual sleepiness when used with standard apnea therapy. - Shift work disorder: helps maintain alertness during scheduled work hours.

Modafinil may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate pain. - Nausea: upset stomach or vomiting. - Insomnia: difficulty falling or staying asleep. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reactions. - Cardiovascular events: chest pain, arrhythmia, or hypertension. - Psychiatric symptoms: hallucinations or severe depression.

Before prescribing Modafinil, clinicians should consider several safety factors.

- Medical evaluation: assess cardiovascular health before initiating therapy. - Concomitant CNS stimulants: avoid combining with other stimulants to reduce risk of overstimulation. - Psychiatric history: monitor patients with depression or psychosis for worsening symptoms. - Pregnancy and lactation: use only if potential benefit outweighs risk; discuss with prescriber. - Liver or kidney impairment: dose may need adjustment; monitor function. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture and light.

Modafinil can interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase modafinil plasma levels. - CYP2C19 inhibitors (e.g., fluvoxamine): can raise exposure and risk of adverse effects. - Oral contraceptives: modafinil may reduce hormonal efficacy, increasing risk of unintended pregnancy.

Moderate Interactions (Monitor Closely): - CYP2C19 inducers (e.g., rifampin, carbamazepine): may lower modafinil concentrations. - Antidepressants (e.g., SSRIs, SNRIs): may increase risk of serotonin syndrome or anxiety. - Antihypertensives: modafinil may diminish blood‑pressure‑lowering effects.